At Axcelead, we’re dedicated to developing selective kinase inhibitors using our kinase panel assay. With a 1.5 million compound library inherited from a pharmaceutical company, we’ve identified potent compounds against 122 kinases, known as A-SKIP, Axcelead Selective Kinase Inhibitor Profiler. We’re expanding this valuable asset.

We’re actively seeking partners to advance kinase drug discovery with these selective compounds. Let’s jumpstart Lead Generation together using A-SKIP. Contact us to accelerate your protein kinase drug discovery project!